Gene Therapy for Adenosine Deaminase (ADA)-SCID

Type: gene_therapy

Status: EMA Approved (Strimvelis), FDA Breakthrough Therapy Designation

Developer: Orchard Therapeutics (Strimvelis), University of California, Los Angeles (UCLA)

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026